27th National Clinical Education Symposium Presentation Abstracts

Actions for Presentation

Download PDF Back to list

Other presentations

Investigation of sociodemographic and clinical data of patients Who hospitalized in Closed Alcohol and Substance Addiction Treatment Center - Page S102
Miray Besir, Başak Bağcı, Aslı Tuğba Esen, Büşra Yıldız

Evaluation of weight, blood lipids, CRP, hemogram values in the first 4 weeks of patients who started clozapine treatment: A retrospective study - Page S103
Nursema Öztürk, Beliz Naz Akyıldız, İlkay Keleş Altun

Evaluation of Different Systemic Inflammatory Markers, CRP and Troponin Levels in Patients Initiated on Clozapine Treatment in a Training and Research Hospital - Page S104
Betül Kurt, Esranur Aliefendioğlu, İlkay Keleş Altun, Sinay Önen

Evaluation of Sociodemographic Characteristics, Disease Characteristics and Treatments of Bipolar Disorder - Page S105
Gökçe Kavak Sinanoğlu

The Ties Between Stress, Rumination, and Resilience in Physicians - Page S106
Nilgün Oktar Erdoğan, İbrahim Mert Erdoğan

Unipolar Mania and Bipolar Disorder: Evaluation from Obssesive Beliefs and Impulsivity Perspective - Page S107
Ecem Aydın, Batuhan Gülırmak, Özge Şahmelikoğlu Onur

29 APRIL 2025, TUESDAY
17.00-18.15 ORAL PRESENTATION SESSION - 9

Metabolic Effects Of Long-Acting Injectable Antipsychotic Use In Patients With Schizophrenia: A Retrospective Study

Şeyda Nur İspir Çaltıner1, Hacer Reyyan Demirel1, Hacer Söylemez1, Elif Yıldız1, Memduha Aydin1

1. Department of Psychiatry, Selcuk University, Konya, Turkey

DOI: 10.5080/kes27.abs77 Page 101

BACKGROUND AND AIM:Schizophrenia requires long-term antipsychotic treatment, which can lead to metabolic side effects like weight gain, dyslipidemia, and insulin resistance.Long-acting injectable(LAI) antipsychotics improve treatment compliance, and this study examines the prevalence of MetS in patients.
METHODS:This study was conducted in the Psychotic Disorders Outpatient Clinic of Selcuk University Faculty of Medicine. Patients aged 18-65 were screened between 2020-2025. Sociodemographic, clinical and body measurement data were collected from hospital medical records. Ethical approval was obtained from the Selcuk University Ethics Committee(2023-434).
RESULTS:A total of 113 schizophrenia patients were included in the study, 40 of the patients were female (64.6%) and 73 were male (35.4%); mean age was 41.74 ± 11.50 years. The 11.5% (n = 13) of patients were treated with first-generation (FGA)-LAI: haloperidol (n=9, 8%) and zuclopenthixol (n=4, 3.5%). The remaining 88.5% (n= 100) of the sample was treated with second-generation (SGA)-LAI: paliperidone monthly (n=41, 36.3%), paliperidone 3 monthly (n=30, 26.5%), aripiprazole (n=26, 23%) and risperidone (n=3, 2.7%). 50 patients (44.2%) met the criteria for MetS. Among the different LAI antipsychotics used, paliperidone three-monthly had the highest MetS prevalence (60.0%), followed by aripiprazole (57.7%) and haloperidol (55.6%), paliperidone monthly (26.8%). No statistically significant difference was found between the average long-acting usage times and ages of patients of those with and without MetS (5.10±2.5 and 5.53±2.97, p<0.05; 42.4±10.8 and 41.2±12.3, p<0.05). There was no difference between genders in terms of MetS. FGA-LAI or SGA-LAI didn’t differ in terms of MetS.
CONCLUSIONS:Studies have shown that patients with schizophrenia have a significantly higher risk of developing MetS compared to the general population. This study further emphasizes the high prevalence of MetS among schizophrenia patients treated with LAI antipsychotics. Given the well-documented complications associated with MetS, routine metabolic screening, early detection, and preventive interventions should be an integral part of schizophrenia treatment.